Aptevo Therapeutics financials
$1.86−2.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $3.1M | $12.3M | $4.3M | $0.00 | $23.1M | $14.7M | $10.0M |
| Gross profit | $0.00 | $0.00 | $0.00 | $3.1M | $12.3M | $4.3M | $0.00 | $11.9M | $9.6M | -$2.5M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | — | 51.4% | 65.8% | −24.9% |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M | -$27.5M | -$41.0M | -$51.7M | -$53.9M | -$138.8M |
| Net income | -$27.5M | -$24.1M | -$17.4M | $8.0M | -$28.5M | -$17.8M | -$40.4M | -$53.7M | $7.0M | -$112.4M |
| Net margin | — | — | — | 257.8% | −231.5% | −411.9% | — | −232.8% | 47.6% | −1125.8% |
| Diluted EPS | $-87.27 | $-31460.23 | $-834058.80 | $920145.60 | $-3557505.60 | $-3065198.40 | $-8123068.80 | $-19610236.80 | $2707689.60 | $-45538416.00 |
| EBITDA | -$26.1M | -$24.3M | -$28.3M | -$27.7M | -$20.3M | -$26.1M | -$38.7M | -$49.3M | -$50.8M | -$64.4M |
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M | -$29.3M | -$42.4M | -$51.4M | -$41.6M | -$36.9M |
| Free cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.1M | -$22.4M | -$29.4M | -$42.5M | -$52.4M | -$43.0M | -$39.4M |
| Diluted shares | 0.3M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M | $40.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $3.5M | $15.4M | $25.1M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M | $53.5M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M | $37.0M |
| Shareholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M | $16.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology